Projects

Projects

BACKGROUND
In 2013, the European Commission launched the 7th Framework Program. Four projects were selected: A-ParaDDisE, KINDReD, NMTrypI and PDE4NPD.

As part of the negotiation process, the European Commission called for strong cooperation and synergy amongst the four projects in order to maximize the impact of the EU funds received.

The representatives of the four Consortia met in Paris, France, on December 5th 2013 in the occasion of the Paris-based DNDi meeting: 10 years of research in neglected infectious diseases. The meeting gave an opportunity for members to come together and discuss on potential areas of synergies.

All of the four Consortia have representatives of GSK (Glazo SmithKline) in their Scientific Advisory Board (SAB), and three of them (PDE4NPD, MNTrypI and KINDReD) share Dr. Eric Chatelain, Head of DNDi, as SAB Member,

The four Consortia met again on September 17th 2014 in the occasion of NMTrypI and KINDReD Consortium meeting in Porto, Portugal, and concrete Synergy activities have been planned. The EC Project Officer, Mr. Hannu Laang, and SAB members also joined the meeting.

The Coordinators of the "Synergy projects" meet regularly via teleconference every three monthes in order to assure the development of the activities.

SCOPE OF SYNERGIES

  1. To foster cooperation and positive spill overs among four funded projects focused on drug development in Neglected Parasitic Diseases in order to assure the best value for the public money granted.

  2. To identify and develop specific concepts concerning in vitro (cell screening) and in vivo (animal testing) candidate drugs to be shared among the four funded projects.

  3. To perform activities among the four projects that can help the communication, analysis process and create a larger platform for dissemination of the projects' results.

AREAS OF SYNERGIES

  • TPP (Target Product Profile)
  • Standardized procedures and animal testing
  • Novel proteomic approaches for on/off target drug interactions
  • Common database for further EU involvement in neglected infectious diseases
  • Communication and dissemination activities
  • Relations with other international initiatives on NPD

Partner-Projects involved in the synergy activities

KINDReD: Kinetoplastid Drug Development

Scientific Coordinator: Dr. Jane MacDougall

Brief description: The KINDReD consortium has been drawn together from academia and industry to strengthen and advance the current drug development pipeline against Trypanosomatid diseases, Leishmaniasis, Human African trypanosomiasis and Chagas disease. KINDReD ambition is to bring much needed new drug candidates through the preclinical development process with the ultimate aim of gaining regulatory approval for initial phase I clinical trials for each of the three major trypanosomatid disease.

Go to the website

A-ParaDDisE: Anti-Parasite Drug Discovery in Epigenetics

Scientific Coordinator: Dr. Raymond J. Pierce

Brief description: The overall objective of the A-ParaDDisE project is to develop optimized epigenetic inhibitors for further testing and optimisation as drug candidates against the four parasites studied (S. mansoni, Leishmania, T. cruzi and Plasmodium sp.).

The Consortium will employ a target-based strategy for the development of novel drug leads against apigenetic targets in schistosomiasis, leishmaniasis, Chagas disease and malaria focusing on key histone modifying enzymes (HMEs), in particular those involved in acetylation/deacetylation and methylation/demethylation.

Go to the website

A-ParaDDisE: Anti-Parasite Drug Discovery in Epigenetics

Scientific Coordinator: Dr. Rob Leurs

Brief description: The PDE4NPD Consortium was established to jointly find drugs for NPDs, targeting phosphodiesterases, in order to find and develop selective inhibitors. The Consortium focuses on three kinetoplastid diseases: human African trypanosomiasis (sleeping sickness), leishmaniasis and Chagas disease, and one major helminth disease: schistosomiasis (also known as biharzia or Snail fever). In order to optimally exploit the generated data, there will be a strong focus on developing an open innovative model for data sharing.

Go to the website